Alsevalimab

艾司沃利单抗

Report date: 2024/11/23 20:00:08

Base Information

Drug NameAlsevalimab
Drug Alias NameFPA-150
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionV-set domain-containing T-cell activation inhibitor 1 inhibitors
TargetsV-set domain-containing T-cell activation inhibitor 1
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFive Prime Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFive Prime Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursEndometrial NeoplasmsOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A